全文获取类型
收费全文 | 1064849篇 |
免费 | 81173篇 |
国内免费 | 7613篇 |
专业分类
耳鼻咽喉 | 13357篇 |
儿科学 | 35160篇 |
妇产科学 | 29315篇 |
基础医学 | 153642篇 |
口腔科学 | 28859篇 |
临床医学 | 99364篇 |
内科学 | 203715篇 |
皮肤病学 | 23637篇 |
神经病学 | 82620篇 |
特种医学 | 40715篇 |
外国民族医学 | 346篇 |
外科学 | 156317篇 |
综合类 | 35571篇 |
现状与发展 | 17篇 |
一般理论 | 387篇 |
预防医学 | 81970篇 |
眼科学 | 24395篇 |
药学 | 79023篇 |
77篇 | |
中国医学 | 5669篇 |
肿瘤学 | 59479篇 |
出版年
2021年 | 10387篇 |
2019年 | 9601篇 |
2018年 | 12895篇 |
2017年 | 10248篇 |
2016年 | 11372篇 |
2015年 | 13658篇 |
2014年 | 18288篇 |
2013年 | 25179篇 |
2012年 | 33639篇 |
2011年 | 36374篇 |
2010年 | 21705篇 |
2009年 | 19859篇 |
2008年 | 32104篇 |
2007年 | 33851篇 |
2006年 | 34459篇 |
2005年 | 33007篇 |
2004年 | 31092篇 |
2003年 | 29936篇 |
2002年 | 28591篇 |
2001年 | 48454篇 |
2000年 | 49667篇 |
1999年 | 42129篇 |
1998年 | 12398篇 |
1997年 | 11414篇 |
1996年 | 11152篇 |
1995年 | 10652篇 |
1994年 | 9852篇 |
1993年 | 8965篇 |
1992年 | 32806篇 |
1991年 | 31952篇 |
1990年 | 31435篇 |
1989年 | 30247篇 |
1988年 | 27472篇 |
1987年 | 27577篇 |
1986年 | 25655篇 |
1985年 | 24753篇 |
1984年 | 18494篇 |
1983年 | 15579篇 |
1982年 | 9319篇 |
1979年 | 16893篇 |
1978年 | 12217篇 |
1977年 | 10314篇 |
1976年 | 9754篇 |
1975年 | 10178篇 |
1974年 | 12317篇 |
1973年 | 11843篇 |
1972年 | 10884篇 |
1971年 | 10113篇 |
1970年 | 9375篇 |
1969年 | 8724篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
31.
32.
33.
34.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention
下载免费PDF全文
![点击此处可从《Journal of advanced nursing》网站下载免费的PDF全文](/ch/ext_images/free.gif)
35.
Stelter K. Theodoraki M. N. Becker S. Tsekmistrenko V. Olzowy B. Ledderose G. 《European archives of oto-rhino-laryngology》2015,272(3):639-639
European Archives of Oto-Rhino-Laryngology - 相似文献
36.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
37.
38.
39.
40.
William G. Breen Krishan R. Jethwa Nathan Y. Yu Grant M. Spears William S. Harmsen Robert C. Miller Jonathan B. Ashman William G. Rule Terence T. Sio Michelle A. Neben-Wittich Michael G. Haddock Amit Mahipal Mark J. Truty Christopher L. Hallemeier Kenneth W. Merrell 《Practical radiation oncology》2021,11(1):e63-e69
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment. 相似文献